Pariet

Pariet decreases the amount of acid produced in the stomach.

Product dosage: 20mg
Package (num)	Per pill	Price	Buy
90	$0.48	$43.00 (0%)	🛒 Add to cart
120	$0.45	$57.33 $54.00 (6%)	🛒 Add to cart
180	$0.43	$86.00 $77.00 (10%)	🛒 Add to cart
270	$0.41	$129.00 $111.00 (14%)	🛒 Add to cart
360	$0.40 Best per pill	$172.00 $144.00 (16%)	🛒 Add to cart

Similar products

Aciphex

Price from 56.00 USD

View

Pariet (rabeprazole sodium) is a proton pump inhibitor (PPI) designed for the effective management of acid-related gastrointestinal disorders. It works by selectively and irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, leading to a pronounced and prolonged suppression of gastric acid secretion. Clinically proven to provide rapid symptom relief and promote mucosal healing, Pariet is indicated for a range of conditions including gastroesophageal reflux disease (GERD), duodenal and gastric ulcers, and Zollinger-Ellison syndrome. Its optimized pharmacokinetic profile ensures consistent bioavailability and a predictable therapeutic response, making it a first-line choice for gastroenterologists and healthcare providers worldwide.

Features

• Active ingredient: Rabeprazole sodium
• Available in 10 mg and 20 mg enteric-coated tablets
• Rapid onset of action with acid suppression observed within one hour
• High bioavailability, not significantly affected by food intake
• Metabolized primarily via non-enzymatic pathways, reducing potential for cytochrome P450-mediated interactions
• Designed for once-daily dosing in most indications

Benefits

• Provides rapid and sustained relief from heartburn, regurgitation, and other GERD symptoms
• Promotes healing of erosive esophagitis and reduces risk of recurrence
• Effective in eradicating Helicobacter pylori when used in combination therapy
• Minimizes nocturnal acid breakthrough, improving sleep quality in patients with nighttime symptoms
• Supports mucosal healing in peptic ulcer disease
• Reduces gastric acid secretion in hypersecretory conditions like Zollinger-Ellison syndrome

Common use

Pariet is commonly prescribed for the treatment of gastroesophageal reflux disease (GERD), including erosive esophagitis and symptomatic GERD. It is also indicated for the healing and maintenance of duodenal ulcers, gastric ulcers, and for use in combination with antibiotics for the eradication of Helicobacter pylori infection in patients with peptic ulcer disease. Additionally, it is used for the long-term management of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Dosage and direction

The recommended adult dosage varies by indication:

• GERD: 20 mg once daily for 4-8 weeks
• Erosive esophagitis maintenance: 10 mg or 20 mg once daily
• Duodenal ulcer: 20 mg once daily for 4 weeks
• H. pylori eradication: 20 mg twice daily as part of combination therapy for 7 days
• Zollinger-Ellison syndrome: Initial dose 60 mg once daily, adjusted based on acid output

Tablets should be swallowed whole with water, preferably in the morning before food. Do not crush, chew, or split tablets as this may damage the enteric coating.

Precautions

• Long-term use (especially beyond one year) may be associated with an increased risk of fractures of the hip, wrist, or spine
• May cause hypomagnesemia, particularly with prolonged therapy; monitor magnesium levels before initiation and periodically during treatment
• Avoid abrupt discontinuation as rebound acid hypersecretion may occur
• Use with caution in patients with severe hepatic impairment; consider dose reduction
• May increase risk of Clostridium difficile-associated diarrhea
• Periodic monitoring of vitamin B12 levels recommended in patients expected to be on long-term therapy

Contraindications

• Hypersensitivity to rabeprazole, substituted benzimidazoles, or any component of the formulation
• Concomitant use with rilpivirine-containing products due to potential for decreased antiviral efficacy
• Patients taking atazanavir due to significant reduction in atazanavir exposure

Possible side effect

Common side effects (≥1/100 to <1/10):

• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Flatulence
• Constipation

Uncommon side effects (≥1/1,000 to <1/100):

• Dizziness
• Insomnia
• Rash
• Dry mouth
• Fatigue

Rare but serious side effects:

• Severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
• Acute interstitial nephritis
• Hypomagnesemia leading to tetany, arrhythmias, or seizures
• Vitamin B12 deficiency with long-term use
• Increased risk of bone fractures with prolonged high-dose therapy

Drug interaction

• May reduce absorption of drugs requiring acidic gastric pH (e.g., ketoconazole, iron salts, dabigatran)
• Potential interaction with clopidogrel due to CYP2C19 inhibition (clinical significance uncertain)
• May increase exposure to methotrexate
• Can affect concentrations of drugs metabolized by CYP2C19 (e.g., phenytoin, warfarin - monitor INR)
• Concomitant use with high-dose methotrexate may increase methotrexate levels

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed dose. Maintain the regular dosing schedule.

Overdose

Experience with rabeprazole overdose is limited. Reported doses up to 80 mg have not produced serious adverse effects. Symptoms would be expected to be consistent with the known pharmacological effects of PPIs. There is no specific antidote; treatment should be symptomatic and supportive. Hemodialysis is not effective due to high protein binding.

Storage

Store at room temperature (15-30°C or 59-86°F) in the original container. Keep tightly closed and protect from moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Pariet is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Dosage and treatment duration should be determined by a physician based on individual patient needs and medical history. Patients should discuss potential risks and benefits with their healthcare provider before starting treatment.

Reviews

Clinical studies have demonstrated Pariet’s efficacy in multiple acid-related disorders. In a randomized controlled trial involving patients with erosive GERD, 20 mg Pariet once daily achieved complete endoscopic healing in 93% of patients after 8 weeks of treatment. Combination therapy with Pariet and antibiotics has shown H. pylori eradication rates exceeding 85% in intention-to-treat analyses. Long-term maintenance therapy with 10 mg daily has been shown to prevent relapse in 93% of patients with healed erosive esophagitis over 52 weeks. Real-world evidence supports the favorable safety profile observed in clinical trials, with most patients reporting significant improvement in quality of life measures.